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Introduction 
The demand for platelets in England was stable at around 220,000 adult 
therapeutic doses (ATD) per year until 2007/8 at which point demand has 
increased year on year to 275,000 ATD in 2014/15, an increase of 25%. 
Similar rises in demand have been seen in Australia and the United States. A 
recent review which considered causes for this dramatic rise identified that an 
ageing population and an increase in the incidence of haematological 
malignancies (with increased treatment intensity, duration and survival) 
accounted for most of this change (Estcourt 2014). In 2012 the population 
aged over 70 in the UK was 7.5 million. By 2046 this number is expected to 
reach 15 million (Office of National Statistics (ONS) 2013). In addition, since 
1990, the number of haematopoietic stem cell transplants performed in Europe 
has risen from 4,200 to over 30,000 annually (Passweg, et al 2012). 
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Although a national audit of platelet use in haematology identified that 28% of 
transfusions were outside of guidelines (Estcourt, et al 2012b) these findings 
demonstrate less inappropriate use than a previous audit (Qureshi, et al 2007). 
An increase in the proportion of inappropriate use is therefore unlikely to have 
contributed significantly to recent changes in demand (Estcourt 2014).  
Currently up to 67% of all platelets are used in the management of patients 
with haematological malignancies (Cameron, et al 2007, Charlton, et al 2014, 
Greeno, et al 2007, Jones, et al 2013, Pendry and Davies 2011). Much of the 
remainder are used in cardiac surgery (7-10%) and in intensive care (5-9%).  
In contrast to platelet demand, the donor base is steadily dropping with a 35% 
reduction in active donors from 1.893 million in 2000 to 1.231 million in 2015 
(NHS Blood & Transplant data). As the majority of platelets in the UK are 
collected from approximately 14,000 registered platelet donors (apheresis 
platelets), and whole blood donors give blood on average 1.7 times a year this 
could have a significant impact on the future supply (European Blood Alliance 
2015, European Committee (Partial Agreement) on Blood Transfusion CD-P-
TS 2016). 
 
SCOPE 
This guideline aims to provide practical advice on platelet transfusions to help 
clinicians to decide when support is expected to be beneficial and to reduce 
inappropriate use. If the reason for thrombocytopenia is unclear, further 
investigation is required as this is likely to influence management. This 
document will cover practice in adults relevant to the UK and replace the 2003 
BCSH platelet use guideline. A one page summary document is available in 
appendix 1.  The indications for platelet transfusion in children and neonates 
and more general specifications such as cytomegalovirus (CMV) status and 
irradiation are not included, and can be found elsewhere (New, et al 2016, 
SaBTO 2012, Treleaven, et al 2011). 
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Methodology 
 
The classification of platelet transfusion into either ’therapeutic‘ to treat 
bleeding or ’prophylactic‘ to prevent bleeding was based on the modified WHO 
bleeding score (Table I) (Stanworth, et al 2013a).  Recommendations for 
prophylactic transfusion relate to patients with bleeding scores of 0 or 1 and 
therapeutic transfusion to patients with bleeding scores of 2 or higher. 
 
For each indication, the recommendations include a threshold or target platelet 
count and a suggested dose, when relevant.  
 
The Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) nomenclature was used to evaluate levels of evidence and to assess 
the strength of recommendations. The GRADE criteria are specified on the 
BCSH website 
(http://www.bcshguidelines.com/BCSH_PROCESS/42_EVIDENCE_LEVELS_AND_GRAD
ES_OF_RECOMMENDATION.html ) and the GRADE working group website  
(http://www.gradeworkinggroup.org). 
 
Literature review details 
A search of published literature was undertaken using the evidence from 
several systematic reviews that are either currently being undertaken by 
members of the writing group (Estcourt, et al 2014a, Estcourt, et al 2014b, 
Estcourt, et al 2014c), or that have been recently published (Crighton, et al 
2015, Hedges, et al 2007, Kumar, et al 2014, Lieberman, et al 2013, Nahirniak, 
et al 2015, Pavenski, et al 2013, van Veen, et al 2010, Vassallo, et al 2014, 
Wardrop, et al 2013).  This was supplemented by searching PubMed and the 
UKBTS/SRI Transfusion Evidence Library 
(www.transfusionevidencelibrary.com) up to November 2014 using specific 
search terms relevant to each section of the guidelines. 
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Working Group Membership 
The guideline group was selected to be representative of UK based medical 
(anaesthetics, benign and malignant haematology, haemostasis, transfusion) 
and laboratory experts with practical experience in platelet transfusion.  
 
Review 
Given the breadth of application, the draft guideline was provided to sounding 
board members of the Haemato-oncology, General Haematology, 
Haemostasis and Thrombosis, and Transfusion Task Forces of BCSH for 
comment and subsequent revision.  
 
SUMMARY OF KEY RECOMMENDATIONS  
 If the reason for thrombocytopenia is unclear, further investigation 
is required to determine appropriate management (1A) 
Recommendations for Prophylactic Transfusion of Platelets to Patients 
with Thrombocytopenia Because Of Reversible Bone Marrow Failure 
Where Recovery Is Anticipated  
 Give prophylactic platelet transfusions (platelet transfusions to 
patients who do not have clinically significant bleeding [WHO grade 
0 or 1] and do not require a procedure) to patients with reversible 
bone marrow failure receiving intensive chemotherapy or 
undergoing allogeneic HSCT to maintain a platelet count at or above 
10 x 109/L (1B) 
 Use only one adult dose (one unit) routinely for prophylactic platelet 
transfusions (1A) 
 Consider not giving prophylactic platelet transfusions to well 
patients with no evidence of bleeding who have had an autologous 
stem cell transplant (2B) 
 Consider increasing the threshold for prophylactic platelet 
transfusion to between 10 and 20 x109/L in patients judged to have 
additional risk factors for bleeding. Individual review is required. 
(2C) 
 
5 
 
Recommendations for Prophylactic Transfusion of Platelets to Patients 
with Thrombocytopenia Because Of Chronic Bone Marrow Failure, Where 
Recovery Is Not Anticipated  
 Use a ‘no prophylactic platelet transfusion’ strategy for 
asymptomatic patients with chronic bone marrow failure (including 
those taking low dose oral chemotherapy or azacitidine) (2B) 
 Give prophylactic platelet transfusions to patients with chronic bone 
marrow failure receiving intensive treatment (1B) 
 Manage patients with chronic bleeding of WHO grade 2 or above 
individually, according to the severity of their symptoms and signs. 
Consider a strategy of prophylaxis (e.g. twice a week) (2C) 
 
Recommendations for Prophylactic Transfusion of Platelets to Other 
Patient Groups 
 Use the platelet count thresholds for reversible bone marrow failure 
as a general guide for prophylactic platelet transfusion in patients 
with critical illness in the absence of bleeding or planned 
procedures. (2C) 
 
Recommendations for Prophylactic Platelet Transfusion Prior To 
Procedures or Surgery  
 Whenever possible use a procedure/equipment associated with the 
lowest bleeding risk. Apply local measures, such as compression, to 
reduce the risk of bleeding post-procedure. (1C) 
 Do not give platelet transfusions routinely prior to:  
o bone marrow aspirate or trephine biopsy (1B)  
o peripherally inserted central catheters (PICCs) (2C)  
o traction removal of tunnelled CVCs (2C) 
o cataract surgery (2C) 
 Consider performing the following procedures above the platelet 
count threshold indicated –  
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o venous central lines (both tunnelled and un-tunnelled), 
inserted by experienced staff using ultrasound guidance 
techniques, when the platelet count is > 20x109/L. (1B) 
o lumbar puncture when the platelet count is ≥ 40x109/L. (2C) 
o insertion/removal of epidural catheter when the platelet 
count is ≥80x109/L. (2C) 
o major surgery - when the platelet count is > 50x109/L (1C) 
o neurosurgery or ophthalmic surgery involving the posterior 
segment of the eye when the platelet count  is > 100x109/L 
(1C) 
o percutaneous liver biopsy when the platelet count is > 50 x 
109/L (2B). Consider trans-jugular biopsy if the platelet count 
is below this level (2B) 
 Prior to renal biopsy ensure potential risk factors for bleeding are 
corrected: anaemia (iron and erythropoietin), uraemia (dialysis) (1B). 
If renal biopsy is urgent consider desmopressin (DDAVP) pre-
procedure (1B) or oestrogen if time allows (2B) 
 Avoid platelet transfusion in renal failure since infused platelets will 
acquire a dysfunction similar to the patients’ own platelets and 
platelet transfusion may result in alloimmunisation (1B) 
 
Recommendations for Therapeutic Platelet Transfusions  
 In severe bleeding, maintain the platelet count above 50 x 109/l. 
Consider empirical use for the initial management of major 
haemorrhage (1C). 
 In patients with multiple trauma, traumatic brain injury or 
spontaneous intracerebral haemorrhage maintain the platelet count 
above 100 x 109/l (2C) 
 In patients with bleeding that is not considered severe or life-
threatening, consider platelet transfusion if the platelet count is 
below 30 x 109/l (2C) 
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Recommendations for Platelet Function Disorders (Congenital)  
 For first line treatment or prevention of bleeding, consider 
recombinant factor VIIa (rFVIIa) in Glanzmann thrombasthenia and 
tranexamic acid (TXA) plus desmopressin in other congenital platelet 
function disorders (2B) 
 If pharmaceutical therapies are contraindicated, ineffective or if there 
is high risk of bleeding, consider transfusion of platelets. In 
Glanzmann thrombasthenia, consider HLA-matched platelets. (2C) 
 
Recommendations for Platelet Function Disorders (Acquired)  
 Do not use platelet transfusion pre-procedure when antiplatelet 
agents have not been discontinued (2C) 
 Use general haemostatic measures to treat bleeding in patients 
during treatment with aspirin, P2Y12 antagonists or GPIIa/IIIb 
inhibitors. If necessary, consider drug cessation and reversal of the 
effect of co-prescribed anticoagulants (2C).   
 Use TXA to counteract the effect of anti-platelet agents when a 
risk/benefit assessment would support this (1B) 
 Consider the use of platelet transfusion as an additional measure to 
those suggested above for critical bleeding (2C). 
  Consider platelet transfusion to prevent bleeding in severe 
thrombocytopenia (platelet count < 10 x 109/l) caused by abciximab 
(2C). 
 
Recommendations for Immune Thrombocytopenia  
 Do not use prophylactic platelet transfusions in patients with 
autoimmune thrombocytopenia (‘ITP’) (1C) 
 Only use platelet transfusion prior to a procedure or surgery when 
other treatment has failed and/or the intervention is urgent. Usual 
threshold counts may be unachievable or unnecessary and 
individual case review is required (1C) 
 Give therapeutic platelet transfusions (more than one dose) to treat 
serious bleeding (1C). In ITP consider co-administration of 
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intravenous immunoglobulin in addition to the platelet transfusion 
(2C).  In post-transfusion purpura (PTP) intravenous 
immunoglobulin is the treatment of choice (1C)  
Contraindications to Platelet Transfusions  
 In patients with thrombotic microangiopathies only use platelet 
transfusions to treat life-threatening bleeding (1C) 
 
Risks from Platelet Transfusions  
 Hospitals should establish a strategy to maximise the transfusion of 
ABO compatible platelets especially to patients who require regular 
platelet support (2B).  
 It is acceptable to use ABO incompatible platelets to reduce 
wastage. Platelets tested and negative for high titre haemagglutinins 
and non group O platelets are associated with a lower risk of 
haemolysis. Pooled platelets suspended in PAS would also be 
expected to reduce this risk. (1B).  
 RhD negative girls or women of childbearing potential should 
receive RhD negative platelets. If unavailable RhD positive platelets 
can be given with anti-D prophylaxis. (1B).  
 For RhD negative boys under 18 years of age, those who already 
have anti-D antibodies, and transfusion-dependant adults, the 
platelets of choice are RhD negative. RhD positive platelets should 
be given if RhD negative platelets are unavailable or to prevent 
wastage of RhD positive components. Anti-D prophylaxis is not 
required (1B). 
 In patients with a history of allergic transfusion reactions, apart from 
mild, use platelets suspended in PAS. If reactions continue or are 
severe, washed platelets (resuspended in 100% PAS) may be 
required (1B). 
 All clinical areas where platelet transfusions are administered 
should have access to guidance on the investigation and 
management of acute transfusion reactions to blood and blood 
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components. We recommend that these are based on BCSH 
guidance (Tinegate, et al 2012) (1A). 
 
Recommendations for Platelet Refractoriness 
 ABO matched platelets should be used when available to maximise 
increments (2C) 
 Patients with hypoproliferative thrombocytopenia who are 
refractory to platelet transfusions solely due to non-immune 
factors should not receive HLA-selected platelet transfusion (2C) 
 Patients with hypoproliferative thrombocytopenia who are 
refractory to platelet transfusions and have class I HLA antibodies 
should receive class I HLA-selected platelet transfusion (2C) 
 Patients with hypoproliferative thrombocytopenia who continue to 
be refractory to HLA-selected platelet transfusions and have HPA 
antibodies should receive HPA-selected platelet transfusion (2C) 
 Patients with hypoproliferative thrombocytopenia who are not 
refractory to platelet transfusion should not receive HLA-selected 
or HPA-selected platelets (2C). 
 
Recommendations for Other Alternatives or Additions to Platelet 
Transfusion  
 Administer TXA early in trauma patients who are bleeding/at risk of 
bleeding (1A) 
 Use TXA in surgical patients expected to have greater than a 500 ml 
blood loss, unless contraindications exist (1A) 
 Consider TXA as an alternative or in addition to therapeutic platelet 
transfusion, in patients with chronic thrombocytopenia caused by 
bone marrow failure (2B) 
 In severe perioperative bleeding/bleeding associated with major 
trauma give fibrinogen (concentrate or cryoprecipitate) if plasma 
fibrinogen concentration is < 1.5 g/L or if signs of a functional 
fibrinogen deficit are seen on near patient testing (1C). 
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 Use thrombopoietin receptor agonists in ITP according to 
international guidelines.  At present there is insufficient evidence to 
recommend these agents in other patient categories (1A). 
 
 
PROPHYLACTIC TRANSFUSION OF PLATELETS TO PATIENTS WITH 
THROMBOCYTOPENIA BECAUSE OF REVERSIBLE BONE MARROW 
FAILURE WHERE RECOVERY IS ANTICIPATED  
The evidence for these recommendations is based on studies in patients with 
haematological malignancy causing thrombocytopenia due to the disease or its 
treatment. Other patient populations are considered separately. 
 
Should Prophylactic Platelet Transfusions Be Given Routinely? 
A systematic review identified six randomised-controlled trials (RCTs) that 
compared a prophylactic versus therapeutic platelet transfusion  strategy 
(Crighton, et al 2015). Four of the included studies were conducted at least 30 
years ago and used outdated methods of platelet component production and 
patient supportive care. Two included studies were recent large RCTs 
(Stanworth, et al 2013a, Wandt, et al 2012). Both of these recent studies 
showed that prophylactic platelet transfusions reduced the risk of bleeding 
when all patients with haematological malignancies receiving treatment (e.g. 
chemotherapy or transplantation) were considered (Crighton, et al 2015), but 
this effect was not seen in a pre-specified sub-group  ‒ patients receiving 
autologous haematopoietic stem cell transplants (HSCT) (Table II) (Stanworth, 
et al 2014). This finding indicates that prophylactic transfusion should continue 
to be the standard of care in patients receiving intensive chemotherapy or 
allogeneic transplantation but may not be appropriate in low risk groups with 
short periods of thrombocytopenia.  
 
 
What Platelet Transfusion Threshold Should Be Used? 
A systematic review identified three RCTs that compared different platelet 
transfusion  thresholds (Estcourt, et al 2012a). Two compared a threshold of 
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20 x 109/L vs. 10 x 109/L, whereas the third compared a threshold of 30 x 109/L 
vs. 10 x 109/L. A fourth RCT excluded from the systematic review compared a 
threshold of 20 x 109/L vs. 10 x 109/L (Zumberg, et al 2002). A meta-analysis of 
all four studies (658 patients) showed that the 10 x 109/L threshold was not 
associated with increased bleeding in comparison with a higher threshold and 
also showed a significant reduction in the number of platelet transfusions given 
(Estcourt, et al 2011). However, this meta-analysis may not be sufficiently 
powered to detect an increased bleeding risk in this lower threshold arm of less 
than 50% (Estcourt, et al 2011).  
 
The use of other transfusion thresholds, such as platelet mass, absolute 
immature platelet numbers and immature platelet fraction have been 
considered as alternatives to a platelet count threshold but there have been no 
randomised studies in adult patients. (Briggs, et al 2006, Eldor, et al 1982, 
Gerday, et al 2009, Zisk, et al 2013). 
 
What Platelet Transfusion Dose Should Be Used? 
A systematic review identified six RCTs that compared different platelet 
transfusion doses. Four of these studies assessed clinically significant bleeding 
as an outcome measure (usually defined as WHO grade 2 or above).  There 
was no evidence of a difference in the risk of bleeding between low dose (1.1 x 
1011/m2) and standard dose (2.2 x 1011/m2) and between standard dose and 
high dose platelet transfusions (4.4 x 1011/m2). Low dose transfusions 
decreased the total amount of platelets patients received, but at the expense of 
a higher number of transfusions episodes. Increasing the dose from a standard 
to a high dose did not increase the transfusion interval (median 5 days for both 
regimens). The mean UK adult platelet dose (one unit of platelets) is around 3 
x 1011 platelets, equivalent to between the low and standard doses defined 
above, although there is evidence of considerable variation (Pietersz, et al 
2012).  
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Additional Risk Factors for Bleeding 
Numerous clinical factors have been reported to be associated with an 
increased risk of bleeding (Table III). However, the majority of these postulated 
risk factors are based on low level evidence, such as expert opinion or 
retrospective analysis of patient databases. Inflammation has been shown to 
be associated with an increased risk of bleeding in mice (Goerge, et al 2008). 
Although studies have differed in their opinion of whether fever increases the 
risk of bleeding in humans (Table III), currently, the platelet transfusion 
threshold is commonly raised to 20 x 109/L when patients have an infection or 
fever (Estcourt, et al 2012b). Further studies are required to identify clearly 
which factors should prompt an increase in the transfusion threshold, and what 
this threshold should be. 
 
Recommendations 
 Give prophylactic platelet transfusions (platelet transfusions to 
patients who do not have clinically significant bleeding [WHO grade 
0 or 1] and do not require a procedure) to patients with reversible 
bone marrow failure receiving intensive chemotherapy or 
undergoing allogeneic HSCT to maintain a platelet count at or above 
10 x 109/L (1B) 
 Use only one adult dose (one unit) routinely for prophylactic platelet 
transfusions (1A) 
 Consider not giving prophylactic platelet transfusions to well 
patients with no evidence of bleeding who have had an autologous 
stem cell transplant (2B) 
 Consider increasing the threshold for prophylactic platelet 
transfusion to between 10 to 20 x109/L in patients judged to have 
additional risk factors for bleeding. Individual review is required. 
(2C) 
 
PROPHYLACTIC TRANSFUSION OF PLATELETS TO PATIENTS WITH 
THROMBOCYTOPENIA BECAUSE OF CHRONIC BONE MARROW 
FAILURE, WHERE RECOVERY IS NOT ANTICIPATED  
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There is little evidence to inform practice. A retrospective study considered 
platelet transfusion in outpatients with stable chronic severe aplastic anaemia 
(AA) (Sagmeister, et al 1999). Prophylactic platelets were given if the count 
was 5x109/l or less. In total 55,239 patient days were reviewed with 18,706 
days when the platelet count was 10x109/l or less. All deaths from 
haemorrhage were associated with alloimmunisation or withdrawal from 
treatment. Three non-fatal major bleeding episodes occurred. The authors 
concluded that this restrictive policy, with a median transfusion interval of 7 
days, was feasible, safe and economical.  
International guidelines that consider patients with chronic thrombocytopenia 
recommend either a ‘no prophylaxis’ strategy (Kaufman, et al 2015, Liumbruno, 
et al 2009, Schiffer, et al 2001) or prophylaxis below a count of 5x109/l (The 
Board of the German Medical Association on the Recommendation of the 
Scientific Advisory Board 2009). 
 
A major concern in using a threshold of 5x109/l is the reported inaccuracy of 
current automated counters when the platelet count is very low (De la Salle, et 
al 2012, Segal, et al 2005). 
 
A policy of prophylaxis has an impact on resources and on patient quality of 
life.   
 
Recent BCSH guidelines for the diagnosis and management of adult AA and 
for the diagnosis and management of adult myelodysplastic syndromes (Killick, 
et al 2015, Killick, et al 2014) advise a no prophylaxis strategy for patients who 
are not receiving active treatment with the latter including patients taking low 
dose oral chemotherapy or azacitidine (Killick, et al 2014). 
 
Recommendations 
 A no prophylaxis platelet transfusion strategy should be used for 
patients with asymptomatic chronic bone marrow failure (including 
those taking low dose oral chemotherapy or azacitidine) (2B) 
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 Prophylactic platelet transfusion should be given to patients with 
chronic bone marrow failure receiving intensive treatment (1B) 
 Patients with chronic bleeding of WHO grade 2 or above require 
individual management according to the severity of their symptoms 
and signs. A strategy of prophylaxis (e.g. twice a week) should be 
considered (2C) 
 
PROPHYLACTIC TRANSFUSION OF PLATELETS TO OTHER PATIENT 
GROUPS 
Platelet function defects, immune-mediated thrombocytopenia and thrombotic 
thrombocytopenic purpura are considered in later sections.   There is little 
evidence to guide practice in other patient populations. One patient group who 
are significant users of prophylactic platelet transfusions are those in critical 
care. A large observational study of critically ill patients showed that 9% 
(169/1923) of all critically ill patients received platelet transfusions and 55% 
(296/534 units) of these were given on days when no significant bleeding 
occurred (Stanworth, et al 2013b). The optimal platelet transfusion 
management of these patients (Lieberman, et al 2013) may differ depending 
upon the underlying clinical diagnosis (Assir, et al 2013).  
 
As the evidence base in non-haematological patients is sparse we have 
extrapolated the evidence from studies in haematology patients to this 
population as a basis for our recommendation until further evidence is 
available. 
 
Recommendation 
 Platelet count thresholds used for reversible bone marrow may be 
used as a general guide for prophylactic platelet transfusion in 
patients with critical illness in the absence of bleeding or planned 
procedures (2C) 
 
PROPHYLACTIC PLATELET TRANSFUSION PRIOR TO PROCEDURES 
OR SURGERY  
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Bone Marrow Aspirates and Trephine Biopsies 
According to the confidential registry of complications after bone marrow 
aspirates and trephines the risk of significant bleeding is very low (less than 1 
in 1,000), and the majority of patients with bleeding did not have significant 
thrombocytopenia (Table IV). Maintaining pressure on the biopsy site until 
bleeding has stopped is advised. 
 
Central Venous Catheters  
Seventeen observational studies have reported bleeding outcomes in 
thrombocytopenic patients after insertion of central venous catheters (CVCs) 
(Table V). Only one case of severe bleeding (Hb drop >15 g/L) was reported 
throughout all of these studies (Weigand, et al 2009). Three studies reported 
on risk factors, in addition to thrombocytopenia, associated with bleeding. In 
two of these studies ultrasound guidance was not used and on multivariable 
analysis the risk of bleeding was significantly increased by the number of 
attempts, site of insertion (jugular vs. subclavian) and failed guide-wire 
insertion (Barrera, et al 1996, Fisher and Mutimer 1999). In the third study 
where ultrasound guidance was used no such correlation was identified 
(Zeidler, et al 2011). Systematic reviews of complications of CVC placement 
(Hind, et al 2003, Randolph, et al 1996) and a more recent small study 
(Tomoyose, et al 2013) found that ultrasound guidance significantly reduced 
failure and complication rates.  
The study by Zeidler looked at the risk of bleeding according to platelet count 
thresholds with multivariable analysis. All CVCs were un-tunnelled and inserted 
by experienced individuals and the analysis was controlled for sex, type of 
leukaemia, insertion site and use of prophylactic platelet transfusions. The risk 
of bleeding only increased when the platelet count was less than 20x109/L (OR 
2.88, 95% CI 1.23 to 6.75, p = 0.015) (Zeidler, et al 2011). In a large study by 
Haas tunnelled CVCs were installed and all bleeding episodes were effectively 
controlled by simple pressure at the site of insertion. The platelet count 
threshold for insertion was 25x109/L (Haas, et al 2010). 
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One additional prospective study assessed insertion of peripherally inserted 
central catheters (PICCs) without prophylactic platelet transfusions. Among the 
50 patients who had a line inserted with a platelet count less than 20x109/L, 
only one bleeding episode occurred (minor oozing) (Potet, et al 2013). 
One prospective non-randomised study assessed the risk of bleeding after 
traction removal of tunnelled cuffed CVCs in patients with abnormal platelet 
counts or an increased International Normalised Ratio (INR) (Stecker, et al 
2007). 14 of the 179 patients enrolled in the study had a time to haemostasis 
of over 5 minutes and only one of these patients had a platelet count < 
100x109/L. 
 
Lumbar Punctures and Neuraxial Anaesthesia 
A wide-ranging review of the literature has been performed to assess the risk 
of spinal haematoma following lumbar puncture and spinal and epidural 
anaesthesia. The evidence was based on case series, case reports, and 
expert opinion. There was insufficient information to consider epidural and 
spinal anaesthesia separately (van Veen, et al 2010). 
 
The authors recommend that providing the platelet count is stable and no 
additional coagulopathy or platelet function defect is present a platelet count of 
≥ 80x109/L should be used for placing/removing an epidural catheter or 
performing spinal anaesthesia and a count of ≥ 40x109/L for lumbar puncture. 
As the technique for spinal anaesthesia is comparable to that of a lumbar 
puncture, a count of ≥ 40x109/L for both of these procedures and a separate 
threshold of 80 x109/L for epidural anaesthesia would be more logical.   
 
We are aware of no new studies that have contributed to the literature since 
this review. 
 
Liver Biopsy 
2,740 percutaneous liver biopsies were conducted in the HALT-C trial (Seeff, 
et al 2010); only 16 patients (0.6%) had a serious adverse event due to 
bleeding. Percutaneous liver biopsies are considered safe when the platelet 
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count is at least 50 to 60 x 109/L (British Society of Gastroenterologists (BSG) 
2004, Rockey, et al 2009). Below this level transjugular liver biopsy (TJLB) 
should be considered. This procedure has been shown to be safe in patients 
with low platelet counts and with modern techniques can produce comparable 
histological samples to those from a percutaneous route (Kalambokis, et al 
2007, Mammen, et al 2008, Wallace, et al 2003). 
 
Renal Biopsy 
Patients with uraemia have a platelet dysfunction which is thought to be 
associated with von Willebrand factor (Hedges, et al 2007). Uncontrolled 
hypertension, high serum creatinine, anaemia, older age and female sex have 
been shown to be risk factors for bleeding following renal biopsy and to 
prolong the bleeding time (Manno, et al 2004, Torres Munoz, et al 2011, 
Whittier 2004, Zhu, et al 2014). Reversal of these problems by treatment of 
hypertension (Zhu, et al 2014), dialysis (Hedges, et al 2007, Mannucci 2012), 
the use of desmopressin (Hedges, et al 2007, Manno, et al 2011, Mannucci, et 
al 1983) or conjugated oestrogens (Mannucci 2012) and the correction of 
anaemia (Hedges, et al 2007) have all been reported to reduce the risk of 
bleeding in non-RCTs . Although treatment of anaemia with recombinant 
human EPO can take many weeks a more rapid effect on haemostasis has 
been noted. This may be through improved platelet adhesion and aggregation 
(Cases, et al 1992, Zwaginga, et al 1991) and an increase in the number of 
reticulated platelets within 7 days (Tàssies, et al 1998).  
 
Transjugular renal biopsy has been used in patients in whom percutaneous 
renal biopsy has failed or been contraindicated and has produced a similar 
diagnostic yield and safety profile (Cluzel, et al 2000). Platelet transfusion is 
likely to be ineffective or at best very short lived as the same dysfunction 
affecting the patient’s own platelets will be acquired. The transfusion may also 
be harmful in patients who progress to renal transplant, because of the risk of 
alloimmunisation (Scornik, et al 2013). 
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Dental Extraction 
One recent small RCT (23 patients requiring 35 procedures and 84 teeth 
removed) has shown a low rate of bleeding complications without blood 
product support, in patients prior to liver transplantation (Perdigão, et al 2012). 
Patients had platelet counts ≥ 30x109/L, an INR ≤ 3.0 and were randomised to 
the presence or absence of tranexamic acid on gauze used to apply local 
pressure. A third of patients had a platelet count < 50x109/L. Only one patient 
in the control arm had post-operative bleeding which was controlled with local 
pressure. Further research is required before a recommendation can be made 
to use local haemostatic measures alone. 
 
Surgery 
There remains a lack of evidence to guide the prophylactic use of platelet 
transfusions before major surgery. Guidelines from around the world suggest a 
threshold of 50 x 109/l before major surgery (BCSH 2003, Liumbruno, et al 
2011, Miller, et al 2007, Samama, et al 2006), and a threshold of 100 x 109/l 
prior to neurosurgery or ophthalmic surgery involving the posterior segment of 
the eye, because of the critical sites involved (BCSH 2003, Liumbruno, et al 
2011, Miller, et al 2007, Samama, et al 2006). Cataract surgery is an avascular 
procedure and therefore platelet transfusions are not routinely required. 
Measurement of the platelet count increment following platelet transfusion pre-
procedure is desirable, but may be limited by the circumstances. 
 
Recommendations 
 Whenever possible use a procedure/equipment associated with the 
lowest bleeding risk. Apply local measures, such as compression, to 
reduce the risk of bleeding post procedure. (1C) 
 Do not give platelet transfusions routinely prior to:  
o bone marrow aspirate or trephine biopsy (1B)  
o peripherally inserted central catheters (PICCs) (2C)  
o traction removal of tunnelled CVCs (2C) 
o cataract surgery (2C) 
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 The following procedures may be performed above the platelet 
count threshold indicated –  
o venous central lines (both tunnelled and un-tunnelled), 
inserted by experienced staff using ultrasound guidance 
techniques, when the platelet count is > 20x109/L (1B) 
o lumbar puncture when the platelet count is ≥ 40x109/L (2C) 
o insertion/removal of epidural catheter when the platelet 
count is ≥ 80x109/L (2C) 
o major surgery - when the platelet count is > 50x109/L (1C) 
o neurosurgery or ophthalmic surgery involving the posterior 
segment of the eye when the platelet count  is > 100x109/L 
(1C) 
o percutaneous liver biopsy when the platelet count is > 50 x 
109/L (2B). Consider trans-jugular biopsy if the platelet count 
is below this level (2B) 
 Prior to renal biopsy ensure potential risk factors for bleeding are 
corrected: anaemia (iron and EPO) uraemia (dialysis) (1B). If renal 
biopsy is urgent consider DDAVP pre-procedure (1B) or oestrogen if 
time allows (2B) 
 In renal failure platelet transfusion should be avoided as infused 
platelets will acquire a dysfunction similar to the patient’s own 
platelets and may result in alloimmunisation (1B) 
 
THERAPEUTIC PLATELET TRANSFUSIONS  
There is little evidence for the effectiveness of platelet transfusions or the 
optimal dose when a patient with thrombocytopenia is actively bleeding i.e. 
WHO grade 2 or above (Estcourt, et al 2013). This may reflect the challenges 
involved in conducting trials in these often complex clinical settings and also 
the fact that platelet dysfunction may develop with major exsanguinating 
bleeding which is not captured by measuring the platelet count (Wohlauer, et al 
2012). One recent large national audit reported the resolution of bleeding after 
a therapeutic platelet transfusion in 58% of cases with clinically significant 
bleeding (WHO grade 2 or above) (Estcourt, et al 2012b).  
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Current recommendations are based on consensus guidelines from around the 
world (BCSH 2003, Liumbruno, et al 2011, Miller, et al 2007, National Blood 
Authority 2011, Rossaint, et al 2010, Samama, et al 2006, Spahn, et al 2013) 
and recently revised BCSH guidelines for major haemorrhage (Hunt, et al 
2015). 
 
Recommendations 
 Severe bleeding, maintain the platelet count above 50 x 109/l. 
Consider empirical use for the initial management of major 
haemorrhage (1C). 
 In patients with multiple trauma, traumatic brain injury or 
spontaneous intracerebral haemorrhage maintain the platelet count 
above 100 x 109/l (2C) 
 In patients with bleeding that is not considered severe or life-
threatening, consider platelet transfusion if the platelet count is 
below 30 x 109/l (2C) 
 
PLATELET FUNCTION DISORDERS (CONGENITAL)  
Glanzmann Thrombasthenia (GT) is usually a severe bleeding disorder in 
which many patients do not express αIIbβ3 integrin on the platelet surface. This 
increases the risk of alloimmunisation to platelet antigens and refractoriness to 
platelet transfusion, which may prevent the effective treatment of bleeding 
(Bakdash, et al 2008, Hayward, et al 2006). Recombinant Factor VIIa (rFVIIa; 
NovoSeven, Novo Nordisk Limited) is licensed as a pro-haemostatic treatment 
in GT patients with anti-platelet antibodies and platelet refractoriness. 
However, most UK experts also advocate rFVIIa first line for the treatment or 
prevention of bleeding in GT, and that rFVIIa plus platelet transfusion should 
be considered for refractory bleeding or before high bleeding-risk surgery 
(Bolton-Maggs, et al 2006). In less severe heritable platelet function disorders, 
including Bernard-Soulier syndrome, TXA and desmopressin may be sufficient 
for haemostasis.  
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Recommendations 
 For first line treatment or prevention of bleeding, consider rFVIIa in 
Glanzmann thrombasthenia and TXA plus desmopressin in other 
congenital platelet function disorders (2B) 
 If pharmaceutical therapies are contraindicated, ineffective or if there 
is high risk of bleeding, consider transfusion of platelets. In 
Glanzmann thrombasthenia, consider HLA matched platelets. (2C) 
 
PLATELET FUNCTION DISORDERS (ACQUIRED)  
Anti-Platelet Agents 
If a patient has recently ingested an anti-platelet agent any platelets transfused 
prior to or during the onset of action of the drug will acquire the same defect as 
the patients’ own platelets (Makris, et al 2013) (Table VI). The effect of platelet 
transfusion to control bleeding outside of this critical period is unclear. A recent 
randomised controlled trial of 190 adults taking anti-platelet agents with 
spontaneous intracranial haemorrhage found no evidence to support the use of 
platelet transfusions (Baharoglu, et al 2016). This confirms the findings of two 
systematic reviews examining the treatment of adults on anti-platelet agents 
with spontaneous or traumatic intracranial haemorrhage which found no 
evidence of a benefit, however all included studies were of low or very low 
quality (Batchelor and Grayson 2012, Nishijima, et al 2012). In vitro 
experiments and a case report suggest that platelet dysfunction caused by 
aspirin is much easier to correct with platelet transfusion than treatment with 
clopidogrel or ticagrelor (Godier, et al 2015, Hansson, et al 2014, Li, et al 2012, 
Vilahur, et al 2007). A pilot study in 14 healthy volunteers supported these in 
vitro findings as two units of platelets was shown to overcome clopidogrel-
induced low platelet reactivity but there was no improvement in ADP-induced 
platelet aggregation (Pruller, et al 2011).   
 
Platelet transfusion to reverse the effects of aspirin is usually unnecessary as 
although it increases the risk of surgical bleeding 1.5-fold, it does not increase 
bleeding severity for most procedures (Makris, et al 2013).  
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In addition to concerns regarding efficacy of platelet transfusion for anti-platelet 
agents other than aspirin, many patients who are prescribed these drugs are at 
high risk of arterial thrombosis and a platelet transfusion may increase this risk 
(Makris, et al 2013). In the randomised controlled trial of spontaneous 
intracranial haemorrhage in patients on anti-platelet agents by Baharogluas, 
identified above, as well as no evidence of benefit the odds of death or 
disability at 3 months were higher in those who received platelet transfusion 
compared to those who received standard care. 
In a pilot study of 14 patients administered two units of platelets 1 to 2 hours 
prior to urgent surgery to “transiently reverse” the effects of aspirin and 
clopidogrel, one patient developed acute coronary syndrome 4 days after 
surgery (aspirin and clopidogrel had been started 6 and 24 hours after surgery, 
respectively) (Thiele, et al 2012).  
 
In contrast TXA has been used in three randomised controlled trials in patients 
taking clopidogrel (with or without aspirin) before coronary artery bypass 
grafting (total 766 patients) and significantly reduced blood transfusion 
requirements (Ahn, et al 2012, Shi, et al 2013a, Shi, et al 2013b). No 
difference in adverse events were reported between the groups however the 
authors advised caution regarding the small numbers and limited follow up (in 
the two largest studies follow up was for one year). 
 
Uraemia  
Management of the acquired anti-platelet effect of uraemia is discussed in the 
section above on Platelet transfusion prior to procedures and surgery under 
‘Renal biopsy’. 
 
Recommendations 
 Do not use platelet transfusion pre-procedure when antiplatelet 
agents have not been discontinued (2C) 
 Use general haemostatic measures to treat bleeding in patients 
during treatment with aspirin, P2Y12 antagonists or GPIIa/IIIb 
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inhibitors. If necessary, consider drug cessation and reversal of the 
effect of co-prescribed anticoagulants (2C).   
 Use TXA to counteract the effect of anti-platelet agents when a 
risk/benefit assessment would support this (1B) 
 Consider the use of platelet transfusion as an additional measure to 
those suggested above for critical bleeding (2C). 
  Consider platelet transfusion to prevent bleeding in severe 
thrombocytopenia (<10 x 109/l) caused by abciximab (2C). 
 
IMMUNE THROMBOCYTOPENIA  
Primary Immune Thrombocytopenia (ITP) 
ITP is an acquired immune-mediated disorder characterised by isolated 
thrombocytopenia (platelet count <100 × 109/L), in the absence of any obvious 
underlying cause (Provan, et al 2010). Signs and symptoms vary widely; some 
patients have little or no bleeding, whereas others can experience life-
threatening/fatal haemorrhage. Platelet transfusions are not recommended as 
prophylaxis (Provan, et al 2010). The Obstetric Anaesthetists’ Association 
advise that for ITP and gestational thrombocytopenia, if the patient and platelet 
count are stable and coagulation screen normal, neuroaxial blockade can be 
done when the count is >50 × 109/L when performed by a skilled and 
experienced anaesthetist (Lyons and Hunt 2010). Platelets have been used, 
often in association with other treatments, to treat major bleeding (Neunert, et 
al 2011). There are no RCTs, and publications consist of case reports, 
observational studies, and uncontrolled interventional studies. 
 
A review of these studies (Table VII) shows that high-dose or high-frequency 
platelet transfusions have been effective at stopping bleeding, even if the 
platelet count has not been affected. A platelet count rise appears to be more 
sustained if platelet transfusions and intravenous immune globulin are 
administered together (Baumann, et al 1986, Spahr and Rodgers 2008), and 
one study suggests this combination is more effective clinically (Spahr and 
Rodgers 2008). 
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Heparin-Induced Thrombocytopenia (HIT) 
Guidelines on the diagnosis and management of HIT have been published 
(Watson, et al 2012). It has been widely stated that giving a platelet transfusion 
may increase the risk of thrombosis (Hopkins and Goldfinger 2008, Linkins, et 
al 2012, Warkentin 2011). However, the evidence for this is poor and based on 
two case series from the 1970s (16 patients in total) (Babcock, et al 1976, 
Cimo, et al 1979). Two more recent case series (forty-one patients in total) 
have reported no association with thrombosis (Hopkins and Goldfinger 2008, 
Refaai, et al 2010). 
 
Post-Transfusion Purpura (PTP) 
This is a rare condition associated with severe thrombocytopenia following 
blood transfusion and caused by antibodies against platelet specific antigens. 
Bleeding can be serious and fatal. The incidence has reduced since universal 
leucodepletion. Multiparous women are the main at risk group (Bolton-Maggs, 
et al 2014). Management is based on individual case reports and case series 
(Murphy 2013). Current practice is to transfuse high dose intravenous 
immunoglobulin without waiting for the results of laboratory investigations with 
random donor platelets reserved to control severe bleeding.  
 
Recommendations 
 Do not use prophylactic platelet transfusions in patients with 
immune mediated thrombocytopenia (1C) 
 Only use platelet transfusion prior to a procedure or surgery when 
other treatment has failed and/or the intervention is urgent. Usual 
threshold counts may be unachievable or unnecessary and 
individual case review is required (1C) 
 Give therapeutic platelet transfusions (more than one dose) to treat 
serious bleeding (1C). In ITP consider co-administration of 
intravenous immunoglobulin in addition to the platelet transfusion 
(2C).  In PTP intravenous immunoglobulin is the treatment of choice 
(1C)  
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CONTRAINDICATIONS TO PLATELET TRANSFUSIONS  
Thrombotic Thrombocytopenic Purpura (TTP) 
Guidelines on the diagnosis and management of TTP and other thrombotic 
microangiopathies have been published (Scully, et al 2012). Evaluation of the 
effect of platelet transfusions in patients with TTP between different studies are 
affected by differing definitions of TTP and study inclusion and exclusion 
criteria, therefore the evidence base is poor (Estcourt, et al 2013) Table VIII. 
Despite this, data from these studies suggest a significant increase in mortality 
in patients who have received a platelet transfusion (Estcourt, et al 2013, 
Peigne, et al 2012). This may be because platelet transfusions precipitate 
further thrombotic events (Scully, et al 2012). One study has suggested an 
association between a recent platelet transfusion and an increased risk of 
cardiac failure (Gami, et al 2005). 
Recommendations 
 In patients with thrombotic microangiopathies only use platelet 
transfusions to treat life-threatening bleeding (1C) 
 
RISKS FROM PLATELET TRANSFUSIONS  
Platelet transfusions have been associated with all blood transfusion reaction 
types (Bolton-Maggs et al 2014). Table IX. Management of these reactions has 
been described in previous BCSH guidance (Tinegate, et al 2012). Acute 
transfusion reaction (ATR) is the most frequently reported category and largely 
consists of either allergic or febrile non-haemolytic reactions. These are three 
times more frequent with platelet than with red cell transfusion, (Bolton-Maggs, 
et al 2014). 
 
Interventions such as leucodepletion, the use of male donor plasma, irradiation 
and bacterial screening have significantly reduced the risk of harm from 
platelet transfusions. Haemagglutinin testing has reduced the risk of 
haemolysis from the use of minor ABO mismatched units (Berseus, et al 2013). 
To further reduce this risk group A platelets rather than group O platelets are 
held as stock (Bolton-Maggs, et al 2014). A recent review and a laboratory 
study have questioned the wisdom of this strategy providing evidence of 
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potential harm from infusion of mismatched platelet components, particularly in 
patients who are regularly transfused (Blumberg, et al 2015, Zaffuto, et al 
2015). ABO matching of all platelet transfusions would eliminate this risk 
however would have significant resource implications because of the increased 
stock required and associated wastage. Currently ABO matching is achieved in 
around 55% of platelet transfusions (Dunbar, et al 2015). The introduction of 
an artificial platelet additive solution (PAS) to replace plasma has lagged 
behind use in red cells but is now available and has the potential to reduce the 
risk of plasma associated problems. Studies assessing the impact of PAS on 
allergic reactions, a relatively common plasma associated reaction of up to 3% 
if mild reactions are included (Tinegate, et al 2012), report a significant 
reduction (Cazenave, et al 2011, Cohn, et al 2014, Tobian, et al 2014, 
Yanagisawa, et al 2013). This may also be cost effective (Kacker, et al 2013).  
 
Although there is little risk of an acute reaction following transfusion of RhD 
positive platelets to an RhD negative recipient, alloimmunisation can occur 
from red cell contamination (Cid, et al 2015, Kitazawa, et al 2011, 
Moncharmont, et al 2014). The largest study investigating this risk has recently 
been published and anti-D developed in only 1.44% of patients. This was not 
associated with the type of platelet component transfused or whether the 
patient was immunosuppressed (Cid, et al 2015). Current BCSH guidelines 
recommend that for RhD negative patients RhD negative red cells 
 should always be given to women of childbearing potential, patients under 18 
years, those who already have anti-D and transfusion dependant adults 
(Milkins, et al 2013). Prophylactic anti-D is only recommended following 
transfusion of RhD positive platelets to girls and women of childbearing 
capacity but not to females without childbearing capacity or males (Qureshi, et 
al 2014).  
 
Transfusion related acute lung injury (TRALI), was previously more commonly 
reported with plasma-rich components than with red cells. Following the 
introduction of universal leucodepletion and the use of male donor plasma this 
situation is no longer the case with no recorded cases, where concordant 
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antibodies were identified, due to platelets in recent years (Bolton-Maggs et al 
2015). 
To date 33 /40 cases of bacterial transfusion transmitted infection (TTI) (overall 
mortality 28%) reported to SHOT have been associated with platelet 
transfusion.  Since the introduction of bacterial screening in 2010 no proven 
cases of TTI have been described (Bolton-Maggs et al 2015). However, as 
bacterial contamination of platelets is known to occur despite negative 
screening results (Bolton-Maggs et al 2015) and TTI carries a high mortality, 
investigation and recall of associated components should be considered for all 
moderate or severe febrile reactions (Tinegate, et al 2012). 
 
Recommendations 
 Hospitals should establish a strategy to maximise the transfusion 
of ABO compatible platelets especially to patients who require 
regular platelet support (2B).  
 It is acceptable to use ABO incompatible platelets to reduce 
wastage. Units tested and negative for high titre haemagglutinins 
and non group O platelets are associated with a lower risk of 
haemolysis. Pooled platelets suspended in PAS would also be 
expected to reduce this risk. (1B).  
 RhD negative girls or women of childbearing potential should 
receive RhD negative platelets. If unavailable RhD positive 
platelets can be given with anti-D prophylaxis. (1B).  
 For RhD negative boys under 18 years of age, those who already 
have anti-D antibodies, and transfusion-dependant adults, the 
platelets of choice are RhD negative. RhD positive platelets should 
be given if RhD negative platelets are unavailable or to prevent 
wastage of RhD positive components. Anti-D prophylaxis is not 
required (1B). 
 In patients with a history of allergic transfusion reactions, apart 
from mild, use platelets suspended in PAS. If reactions continue or 
are severe, washed platelets (resuspended in 100% PAS) may be 
required (1B). 
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 All clinical areas where platelet transfusions are administered 
should have access to guidance on the investigation and 
management of acute transfusion reactions to blood and blood 
components. We recommend these are based on BCSH guidance 
(Tinegate, et al 2012) (1A).  
 
PLATELET REFRACTORINESS  
Refractoriness to platelet transfusion has been studied in a recent review by an 
international panel using two systematic search strategies (Pavenski, et al 
2013, Vassallo, et al 2014) and standardised methods to develop 
recommendations (Nahirniak, et al 2015). Non-immune conditions such as 
consumptive coagulopathy, sepsis and splenomegaly are recognised as the 
most common cause of platelet refractoriness, accounting for approximately 
80% of cases (Doughty, et al 1994, Legler, et al 1997). Alloimmune 
refractoriness in a patient with thrombocytopenia due to bone marrow failure 
was defined as a 10 minute to one hour increment of less than 5 x 109/l on 2 
consecutive occasions, using ABO-identical platelets and in the absence of 
predominantly non-immunological factors. The trials available to address ABO 
matching and refractoriness due to alloimmunisation were of overall low 
quality. There were 30 studies including 1 RTC which considered HLA 
matching and 29 studies with no RCTs which considered cross-matched 
platelets. 
 
Recommendations 
 ABO matched platelets should be used when available to maximise 
increments (2C) 
 Patients with hypoproliferative thrombocytopenia who are 
refractory to platelet transfusions solely due to non-immune 
factors should not receive HLA-selected platelet transfusion (2C) 
 Patients with hypoproliferative thrombocytopenia who are 
refractory to platelet transfusions and have class I HLA antibodies 
should receive class I HLA-selected platelet transfusion (2C) 
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 Patients with hypoproliferative thrombocytopenia who continue to 
be refractory to HLA-selected platelet transfusions and have HPA 
antibodies should receive HPA-selected platelet transfusion (2C) 
 Patients with hypoproliferative thrombocytopenia who are not 
refractory to platelet transfusion should not receive HLA-selected 
or HPA-selected platelets (2C). 
 
OTHER ALTERNATIVES OR ADDITIONS TO PLATELET TRANSFUSION  
Antifibrinolytic Agents 
The antifibrinolytic agent TXA reduces mortality in trauma without increasing 
vascular events (Shakur, et al 2010), and reduces blood loss and transfusion 
requirements during surgery (Ker, et al 2012, Poeran, et al 2014). Recent 
NICE guidance contains a strong recommendation for the use of TXA in adults 
undergoing surgery when blood loss is expected to be greater than 500ml 
(NICE 2015). A Cochrane review (Wardrop, et al 2013) examined 
antifibrinolytic agents and prophylactic platelet transfusion in patients with 
thrombocytopenia due to bone marrow failure. Of the three eligible studies, all 
noted a reduction in bleeding and platelet transfusion with antifibrinolytic 
usage; the review concluded that an appropriately powered RCT was required.  
 
BCSH guidelines recommend short term TXA in thrombocytopenic patients 
with MDS with mucus membrane bleeding, advising caution in patients with 
ischaemic heart disease or haematuria (BCSH 2003, Killick, et al 2014).  
 
Desmopressin  
Desmopressin promotes coagulation by stimulating factor VIII release from 
endothelial stores and increasing vWF activity. Two recent European 
guidelines regarding bleeding in trauma (Spahn, et al 2013) and perioperative 
bleeding (Kozek-Langenecker, et al 2013) advocate desmopressin to improve 
platelet function. In trauma this is recommended for patients receiving aspirin 
and in the perioperative setting in patients with uraemia or inherited platelet 
defects. 
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Fibrinogen 
Fibrinogen concentrate is currently only licenced in the UK for congenital 
deficiency. It has been used to treat bleeding in surgical patients and was 
associated with reduced bleeding and blood product usage in a recent 
systematic review; however the included studies were small and at high risk of 
bias, thus more evidence is required (Wikkelsø, et al 2013). Two recent 
European guidelines (Kozek-Langenecker, et al 2013, Spahn, et al 2013) 
recommend using fibrinogen for haemorrhage where there is evidence of 
fibrinogen deficiency. 
 
Thrombopoietin Receptor Agonists and Other Therapies 
Initial studies of Romiplostim for thrombocytopenia secondary to MDS/NHL 
showed encouraging platelet count improvements (Greenberg, et al 2012, 
Sekeres, et al 2011, Wang, et al 2012); however, in 2011 a larger placebo 
controlled trial in low/intermediate 1 risk MDS patients was discontinued due to 
transient blast cell count increases  (Giagounidis and Kantarjian 2014, 
Kantarjian, et al 2012).  
 
Eltrombopag has also been used in small non-randomised studies in patients 
with advanced MDS/AML and severe AA (Olnes, et al 2012); further studies 
are needed to assess the benefits/risks including clonal progression. In elderly 
patients with aplastic anaemia, BCSH guidelines suggest consideration of use 
of eltrombopag where all other treatment modalities have been explored 
(Killick, et al 2015).   
A large randomised-controlled study using Eltrombopag pre-procedure in 
patients with chronic liver disease was terminated early because of an 
increased incidence of portal vein thrombosis (Afdhal, et al 2012).  
Both Romiplostim and Eltrombopag are licenced and NICE approved for 
treatment in ITP. In a recent retrospective observational study a sustained 
response was achieved in at least 29% after temporary use of these agents 
with a median follow up of more than a year.  (Mahévas, et al 2014).  
Erythropoietin (EPO) has been observed to reduce both red cell and platelet 
transfusion requirements in patients following HSCT and iron chelation has 
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been reported to improve haematopoiesis in patients with iron overload 
(Michallet, et al 2013).  
 
Recommendations 
 Administer TXA early in trauma patients who are bleeding/at risk of 
bleeding (1A) 
 Use TXA in surgical patients expected to have greater than a 500 ml 
blood loss, unless contraindications exist (1A) 
 Consider TXA as an alternative or in addition to therapeutic platelet 
transfusion in patients with chronic thrombocytopenia caused by 
bone marrow failure (2B) 
 In severe perioperative bleeding/bleeding associated with major 
trauma give fibrinogen (concentrate or cryoprecipitate) if plasma 
fibrinogen concentration is < 1.5 g/L or if signs of a functional 
fibrinogen deficit are seen on near patient testing (1C). 
 Use thrombopoietin receptor agonists according to international 
guidelines in ITP.  At present there is insufficient evidence to 
recommend these agents in other patient categories (1A). 
 
PLATELET TRANSFUSION IN TIMES OF SHORTAGE  
Table X provides general guidance for the use of platelet transfusions in the 
context of reduced availability. Category 1 patients are those with the greatest 
clinical need for platelet support and therefore should be given priority when 
considering allocation. Category 3 patients are the lowest priority and should 
be the first to have platelet transfusions withheld.  Patients who have had an 
autologous stem cell transplant have been included in category 3 based on 
evidence from two large RCTs (Stanworth, et al 2013a, Wandt, et al 2012) 
(Table II) and from consideration of the risks associated with platelet 
transfusions (described earlier).  
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TABLES 1 
 2 
Table I: Modified WHO bleeding score (Stanworth et al, 2013a) 3 
Grade Type of bleeding 
Grade 1  Petechiae/purpura that is localized to 1 or 2 dependent sites, or is sparse/non-confluent 
 Oropharyngeal bleeding, epistaxis <30 minutes duration 
Grade 2 
 
 Melaena, haematemesis, haemoptysis, fresh blood in stool, musculoskeletal bleeding, or soft tissue 
bleeding not requiring red cell transfusion within 24 hours of onset and without haemodynamic 
instability 
 Profuse epistaxis or oropharyngeal bleeding >30 minutes 
 Symptomatic oral blood blisters, i.e. bleeding or causing major discomfort 
 Multiple bruises, each >2 cm or any one >10 cm 
 Petechiae/purpura that is diffuse 
 Visible blood in urine 
 Abnormal bleeding from invasive or procedure sites 
 Unexpected vaginal bleeding saturating more than 2 pads with blood in a 24 hr period 
 Bleeding in cavity fluids evident macroscopically 
 Retinal hemorrhage without visual impairment 
51 
 
Grade 3 
 
 Bleeding requiring red cell transfusion specifically for support of bleeding within 24 hours of onset and 
without hemodynamic instability 
 Bleeding in body cavity fluids grossly visible 
 Cerebral bleeding noted on computerized tomography (CT) without neurological signs and symptoms 
Grade 4 
 
 Debilitating bleeding including retinal bleeding and visual impairment* 
 Non-fatal cerebral bleeding with neurological signs and symptoms 
 Bleeding associated with haemodynamic instability (hypotension, >30 mmHg change in systolic or 
diastolic BP) 
 Fatal bleeding from any source 
* visual impairment is defined as a field deficit, and patients with suspected visual impairment require an ophthalmological 4 
consultation5 
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Table II: Data from (Stanworth et al, 2013a) and (Stanworth et al, 2014)  6 
Patient Group Difference in proportion of patients who bled 
(therapeutic versus prophylactic) 
Number of patients needed to be treated with 
prophylactic platelet transfusions to prevent 
1 patient from bleeding within a 30 day 
period 
  95% CI  95% CI 
All patients 8.4 0.3 to 16.5 12 6 to 333 
Autologous stem cell 
transplant patients 
2.3 -7.2 to 11.9 43 Not estimable as no 
significant difference 
between treatment 
arms 
Chemotherapy/allogeneic 
stem cell transplant 
patients 
20.0 5.6 to 34.5 5 3 to 18 
7 
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Table III: Examples of bleeding risks in haematology patients noted in both randomised controlled trials (RCTs) and 8 
observational studies. (Data from RCTs on a specific bleeding risk have been placed before data from 9 
retrospective studies.) Table updated from original (Estcourt, et al 2011) 10 
 11 
Haemorrhagic Risk Study Type of Study No. of 
patients in 
study 
Analysis OR/ HR/ RR/ P value Statistically 
significant 
Baseline 
Characteristics – 
Female Sex 
(Stanworth, et al 
2015) 
RCT 589 M HR 1.33 (95% CI 1.10 to 1.61) Y 
(Kim, et al 2004) 
Retrospective, 
observational 
792 M 
RR 5.23 (95% CI 2.13to 
12.89) 
Y 
(De la Serna, et al 
2008) 
Prospective, 
observational 
732 M P = 0.16 N 
Baseline 
Characteristics -Poor 
risk disease 
(Nevo, et al 2007) 
Retrospective, 
observational 
480 M OR 1.84 (95% CI 1.05 to 3.22) Y 
Baseline 
Characteristics – 
APL vs. other acute 
leukaemia 
(Kim, et al 2004) 
Retrospective, 
observational 
792 M 
RR 4.06 (95% CI 1.63 to 
10.13) 
Y 
(Chen, et al 2009) 
Retrospective, 
observational 
790 U P = 0.001 Y 
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Treatment –  
BM HSCT within 100 d 
(Friedmann, et al 
2002) 
Retrospective,  
observational 
2942 M OR 1.32 (95% CI 1.22 to 1.43) Y 
Treatment –  
Blood & BM HSCT (Lawrence, et al 
2001) 
Prospective,  
interventional 
141 M 
r = 0.174 (major haemorrhage) 
P < 0.001 
r = 0.054 (minor haemorrhage)  
P < 0.001 
Y 
Treatment – 
Allogeneic HSCT or 
chemotherapy vs. 
autologous HSCT 
(Stanworth, et al 
2015) 
RCT 589 M HR 1.43 (95% CI 1.19 to 1.72) Y 
Treatment - HSCT  
(Allogeneic vs. 
Autologous) 
 
(Zumberg, et al 
2002) 
RCT 159 U OR 2.8 (95% CI 1.1 to 7.7) Y 
(Nevo, et al 2007) 
Retrospective, 
observational 
480 M OR 2.29 (95% CI 1.11 to 4.77) Y 
(Gerber, et al 
2008) 
Retrospective, 
observational 
1514 M OR 2.17 (95% CI 1.56 to 3.03) Y 
Infection - bacteraemia (Friedmann, et al 
2002) 
Retrospective, 
observational 
2942 M OR 1.01 (95% CI 0.81 to 1.26) N 
 12 
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Infection – clinical (Webert, et al 
2006) 
Retrospective analysis 
of RCT* 
255 M RR 1.98 (95% CI 1.0 to 3.92) Y 
Infection – systemic (Najima, et al 
2009) 
Retrospective, 
observational 
622 M HR 1.52 (95% CI 0.57 to 4.03) N 
Infection – sepsis (Lawrence, et al 
2001) 
Prospective, 
interventional 
141 M r = 0.024; P = 0.036@ Y 
Fever ≥ 38oC (Stanworth, et al 
2015) 
RCT 469 M HR 1.7 (95% CI 1.3 to 2.4) Y 
Fever – per 10C  rise in 
temp 
(Friedmann, et al 
2002) 
Retrospective, 
observational 
2942 M OR 1.02 (95% CI 0.94 to 1.1) N 
Fever – not specified (Lawrence, et al 
2001) 
Prospective, 
Interventional 
141 M r = 0.072; P < 0.001@ Y 
Fever > 38.5oC 
(Webert, et al 
2006) 
Retrospective analysis 
of RCT* 
255 M 
RR 3.95 (95% CI 1.90 to 8.20) Y 
Fever associated with 
WHO grade 3&4 
haemorrhage only 
RR 1.62 (95% CI 0.44 to 5.91) N 
  13 
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Medication – semi-
synthetic penicillin 
(Lawrence, et al 
2001) 
Prospective, 
Interventional 
141 M r = 0.032; P = 0.014@ Y 
(Friedmann, et al 
2002) 
Retrospective, 
Observational 
2942 M OR 0.94 (95% CI 0.80 to 1.09) N 
Medication – anti-
fungal medication 
(Webert, et al 
2006) 
Retrospective analysis 
of RCT* 
255 M RR 0.59 (95% CI 0.39 to 0.9) Y 
 
 
      
Medication - 
amphotericin 
(Zumberg, et al 
2002) 
RCT 159 M P < 0.0001 Y 
(Lawrence, et al 
2001) 
Prospective, 
Interventional 
141 M 
r = 0.064 (major haemorrhage) 
P < 0.001 
r = 0.114 (minor haemorrhage) 
P < 0.001 
Y 
(Friedmann, et al 
2002) 
Retrospective, 
Observational 
2942 M OR 0.97 (95% CI 0.84 to 1.13) N 
Medication - 
anticoagulants 
(Gerber, et al 
2008) 
Retrospective, 
Observational 
1514 M OR 3.1 (95% CI 1.8 to 5.5) Y 
(Friedmann, et al 
2002) 
Retrospective, 
Observational 
2942 M 
OR 0.94 (95% CI 0.09 to 
10.12) 
N 
57 
 
Laboratory parameters 
-Uraemia  
(urea > 17.9mmol/l) 
(Friedmann, et al 
2002) 
Retrospective, 
 Observational 
2942 M OR 1.64 (95% CI 1.40 to 1.92) Y 
Laboratory parameters 
– platelet count (Lawrence, et al 
2001) 
Prospective, 
Interventional 
141 M 
r = -0.101 (major haemorrhage) 
P < 0.001 
r = -0.144 (minor haemorrhage) 
P < 0.001 
Y 
Laboratory parameters 
- for every 1x109/L 
increase in platelet 
count 
(Webert, et al 
2006) 
Retrospective analysis 
of RCT* 
255 M RR 0.96 (95% C.I. 0.93 to 0.98) Y 
Laboratory parameters 
–  
Platelet count 
0 to 9x109/l 
vs. 
40 to 49x109/l 
(Friedmann, et al 
2002) 
Retrospective,  
Observational 
2942 M 
OR 1.14 (95% C.I. 0.89 to 
1.46) 
(not transfused) 
 
OR 0.98 (95% C.I. 0.69 to 
1.39) 
(transfused) 
N 
 14 
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Other co-morbidities -  
Acute Graft vs Host 
Disease 
(Zumberg, et al 
2002) 
RCT 159 M 
P < 0.049 Y 
(Bleggi-Torres, et 
al 2002) 
Retrospective, 
Observational 
180 U OR 0.86 (95% CI (0.45 to 1.62) N 
(Gerber, et al 
2008) 
Retrospective, 
Observational 
1514 M 
OR 2.4 (95% CI 1.8 to 3.3) Y 
(Najima, et al 
2009) 
Retrospective, 
Observational 
622 M HR 1.41 (95% CI 1.01 to 1.97) Y 
Other co-morbidities –  
Veno-occlusive 
disease 
(Zumberg, et al 
2002) 
RCT 159 M P < 0.033 Y 
(Gerber, et al 
2008) 
Retrospective, 
Observational 
1514 M OR 2.2 (95% CI 1.4 to 3.6) Y 
(Najima, et al 
2009) 
Retrospective, 
Observational 
622 M HR 2.63 (95% CI 0.77 to 9.00) N 
Other co-morbidities 
Splenomegaly 
(Lawrence, et al 
2001) 
Prospective, 
Interventional 
141 M r = 0.055; P < 0.001@ Y 
 16 
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Other co-morbidities 
Recent history of 
severe haemorrhage 
(≤5d) 
(Friedmann, et al 
2002) 
Retrospective, 
Observational 
2942 M OR 6.72 (95% CI 5.53 to 8.18) Y 
APL, acute promyelocytic leukaemia; BM = bone marrow; CI = confidence interval; HR = hazards ratio; HSCT = haemopoietic stem 18 
cell transplantation; M = multivariate analysis; N = no; OR = odds ratio; RCT = randomised controlled trial; RR = relative risk; U = 19 
univariate analysis; Y = yes 20 
* Data from Rebulla et al, 1997 21 
@Minor haemorrhage. No association with major haemorrhage 22 
 23 
24 
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Table IV: Bone Marrow Aspirate and/or Trephine Biopsy. Adverse bleeding events reported in UK confidential 25 
morbidity/mortality reports 26 
Study Study 
period 
No. of 
hospitals 
No. of 
procedures 
No. of  
haemorrhages 
Risk Factors for haemorrhage 
     Thrombocytopenia 
( < 50x 109/l) 
Aspirin Heparin Warfarin DIC Other Obesity Renal 
Impairment 
MDS MPN 
(Bain 2003) 1995 
to 
2000 
34 39,264 
14 1 3 0 1 2 0 2 NR 2 9 
2001 60 19,332 
(Bain 2004) 2002 53 13,506 10 3 4 1 1 0 0 1 2 1 5 
(Bain 2005) 2003 63 19,259 11 2 3 0 1 0 1* 1 0 1 5 
(Bain 2006) 2004 120 20,323 9 0 3 0 0 0 1† 0 0 1 3 
Devalia** 2006 49 15,388 8 1 3 0 1 0 0 3 0 0 4 
Devalia** 2007 NR NR 8 1 0 0 1 1 1† 0 0 0 1 
Devalia** 2008 NR NR 11 3 4 0 1 1 1† 3 0 1 2 
(Devalia 
2013) 
2011 45 9,295 9 6 0 0 0 0 1ⱡ 1 0 2 0 
DIC = disseminated intravascular coagulation; MDS = myelodysplastic syndromes; MPN = myeloproliferative neoplasm; No. = number; NR = 27 
not reported 28 
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* Patient had von Willebrand disease 29 
† Patient had deranged coagulation associated with myeloma 30 
ⱡ Patient had alcohol related problems 31 
** personal communication with Dr Vinod Devalia 32 
33 
62 
 
Table V: Observational studies reporting bleeding outcomes after insertion of venous central line insertions 34 
 35 
Study Study 
duration 
Type of study Number of 
participants 
(procedures) 
Type of patient Definition of 
thrombocytopenia 
Number of 
procedures with 
thrombocytopenia 
Definition of 
coagulopathy 
Number of 
procedures with 
thrombocytopenia 
and/or 
coagulopathy 
Number of 
procedures 
with 
bleeding 
 
Number of 
procedures 
with major 
bleeding 
Number of 
procedures with 
thrombocytopenic 
participants 
bleeding  
(major bleeding) 
(Carr, et 
al 2006) 
Jan’93 
to 
Jun’03 
Observational 
Retrospective 
115 
(NR) 
Acute 
leukaemia 
NR NR* NR NR 0 0 
0 
(0) 
(Mumtaz, 
et al 
2000) 
Sep’97 
to 
Aug’99 
Observational 
Retrospective 
1,825 
(2,010) 
Haematological 
malignancy; 
solid tumours; 
ICU; renal 
failure 
< 150 NR 
INR > 1.3 
aPTT > 37s 
88 4 0 
3 
(0) 
(Foster, et 
al 1992) 
Jan’88 
to 
Dec’88 
Observational 
Retrospective 
40 
(259) 
Liver disease < 80 122 
PT < 40% 
aPTT ≥ 77s 
122 0 0 
0 
(0) 
(Barrera, 
et al 
1996) 
Jul’90 
to 
Sep’93 
Observational 
Prospective 
 
115 
(115) 
Haematological 
malignancy; 
solid tumours 
≤ 50 108 
Prolonged 
PT and aPTT  
8 23 0 
20 
(0) 
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(Cavanna, 
et al 
2010) 
Dec’00 
to 
Jan’09 
Observational 
Prospective 
1,660 
(1,978) 
Haematological 
malignancy; 
solid tumours 
≤ 50 116 NR NR 4† 0 NR 
(Della 
Vigna, et 
al 2009) 
Sep’01 
to 
Aug’08 
Observational 
Retrospective 
157 
(239) 
Haematological 
malignancy; 
solid tumours 
≤ 50 NR 
PT or aPTT 
> 2.2 x 
normal  
45 
1 
 
0 
0 
(0) 
 36 
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(Doerfler, 
et al 1996) 
Oct’92 
to 
Oct‘93 
Observational 
76 
(104) 
Haematological 
malignancy; 
solid tumours; 
liver transplant; 
other 
≤ 50 41 
PT or aPTT 
> 1.5 x 
normal 
76 7 0 
7 
(0) 
(Fisher and 
Mutimer 
1999) 
Jan‘96 
to 
Sep‘97 
Observational 
Prospective 
283 
(658) 
Liver disease ≤ 50 146 INR > 1.5 NR 62 1 
19 
(0) 
(Haas, et al 
2010) 
Jul’01 
to 
Jul’08 
Observational 
Retrospective 
2,514 
(3,170) 
Haematological 
malignancy; 
renal failure; 
other 
≤ 50 344 INR ≥ 1.5 626 3** 1 
0 
(0) 
(Hong 
Pheng Loh 
and Hon 
Chui 2007) 
Jan’02 
to 
Dec’04 
Observational 
Retrospective 
80 
(80) 
Acute 
leukaemia 
< 50 22 NR NR 2 0 
0 
(0) 
(Ray and 
Shenoy 
1997) 
Oct’95 
to 
Sep’96 
Observational 
Prospective 
105 
(112) 
NR < 50 37 NR NR 4 1 
0 
(0) 
(Tercan, et 
al 2008) 
Apr’02 
to 
Jul’06 
Observational 
133 
(133) 
NR ≤ 50 38 
INR ≥ 1.5 or 
aPTT ≥ 50s 
90 8 0 
NR 
(0) 
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(Tomoyose, 
et al 2013) 
Jan’03 
to 
Feb’09 
Observational 
Retrospective 
72 
(108) 
Haematological  
malignancies 
≤ 50 67 NR NR 5 0 
4 
(0) 
(Weigand, 
et al 2009) 
Oct’05 
To 
Apr‘07 
Observational 
Prospective 
196 
(NR) 
Liver disease; 
ICU; renal 
failure; 
haematological 
malignancy 
≤ 50 19 INR > 1.5 51 NR 34 
NR 
(1) 
(Zeidler, et 
al 2011) 
‘01 to 
‘07 
Observational  
Retrospective 
193 
(604) 
Acute 
leukaemia 
≤ 50 173 INR > 1.4 NR 8** 0 
5 
(0) 
 38 
(Duffy and 
Coyle 2013) 
Jan’99 
to 
Jul’11 
Observational 
Retrospective 
55 
(57) 
TTP ≤ 30 29 NR NR 17 0 
10 
(0) 
(Napolitano, 
et al 2013) 
Jan’99 
to 
Jun’09 
Observational 
Retrospective 
431 
Haematological 
disorders 
< 30 39 NR NR 8 0 
1 
(0) 
aPTT = activated partial thromboplastin time; ICU = intensive care unit; INR  =  international normalised ratio; NR =  not reported; PT = prothrombin time; TTP = thrombotic thrombocytopenic purpura 39 
* Median platelet count 72  x 109/l, range 10 to 347 40 
† Patients all had puncture of artery causing a haematoma 41 
**Bleeding in this study is defined as bleeding that required at least pressure at the insertion site to stop bleeding 42 
Major bleeding defined as requiring a red cell transfusion to treat bleeding; haemothorax; significant fall in haemoglobin concentration 43 
44 
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Table VI: Onset of action and half-life of anti-platelet agents 45 
Anti-platelet 
agent 
Onset of action after oral 
administration 
Plasma half-life of active 
drug or metabolite 
Time from drug 
administration when 
any platelet transfusion 
given will have reduced 
efficacy  
(active drug or 
metabolite still present 
in plasma at >25% peak 
drug levels) 
Time to normal platelet 
function/coagulation 
activity after 
discontinuation of drug 
Abciximab Not applicable 30 minutes 1 hour 24 to 48 hours 
Aspirin < 1 hour 
3 to 4 hours with enteric-coated 
preparations 
15 to 20 minutes 2 hours 
4 to 5 hours with enteric-
coated preparations 
5 to 7 days 
Clopidogrel 4 to 8 hours 30 minutes 12 hours 5 to 7 days 
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Dipyridamole 1.25 hours 2 to 3 hours 5 to 7 hours 24 hours 
Eptifbatide Not applicable 2.5 hours 4 hours 4 to 8 hours 
Ibuprofen 45 minutes to 2 hours 2 hours 6 hours 24 hours 
Prasugrel 2 to 4 hours 7 hours 16 to 18 hours 5 to 7 days 
Ticagrelor 1.5 hours 8 to 12 hours 18 to 26 hours 3 to 5 days 
Tirofiban Not applicable 1.5 hours 4 hours 4 to 8 hours 
  46 
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Table VII: Studies that assessed the use of platelet transfusions in patients with autoimmune or drug-induced immune 47 
thrombocytopenia 48 
 49 
Study Study 
Period 
No. 
of 
Pts 
Sex Type Median 
Age 
(Range) 
Bleeding Corticoster
oids at 
Time of Plt 
Tx 
Treatment Post-Rx Platelet 
Count 
Clinical 
Response 
Prospective, interventional, Uncontrolled 
(Baumann, 
et al 1986) 
NR 6 M (2) 
F (4) 
Idiopathic  
(2 previous 
Rx with 
steroids) 
56.5   
(32 to 85) 
1 pt had 
menorrhagi
a 
1 8 units plt tx 
Then 400 mg/kg 
IVIG + 8 units 
plt tx 
Plt increment after 
IVIG + plt tx (median: 
68 × 109/L; range: 20-
130); time to baseline 
>60 hrs 
Plt tx alone (median: 
31; range: 18-33) 
Median time to 
baseline: 6hrs 
1 pt: menorrhagia 
responded to 
IVIG + plt tx, not 
plt tx alone 
(Salama, et 
al 2008) 
NR 10 M (3) 
F (7) 
Chronic, 
refractory 
48 
(24 to 79) 
Severe 
bleeding (5) 
GI bleed (2) 
4 1 unit every 30 
min 
Plt count increased to 
>80 × 109/L in all 
cases; returned to 
Bleeding stopped 
in all cases 
69 
 
3 to 7 apheresis 
units (2.7 × 1011 
plts per unit) 
baseline in 7/10 by 48 
hrs 
 50 
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Retrospective, Observational  
(Carr, et al 
1986) 
Jan 
1981 -
Jul 1984 
11 M (4) 
F (7) 
Idiopathic 
(6) 
Quinidine 
induced (5) 
71 
(25 to 88) 
CNS (2) 
Epistaxis 
(6) 
Upper GI 
(2) 
Petechiae 
alone (1) 
 
Idiopathic 
(6) 
Quinidine 
(1) 
Plt Tx. 
Median/pt 2 
(Range 1 to 6) 
Pooled (28 plt 
tx) 
Apheresis (3 plt 
tx) 
 
7/11 (13/31 tx) 
received “successful 
tx” = increment ≥20 × 
109/L within 5 hrs of 
tx; 5/31 tx plt count 
still higher at 24 hrs 
Idiopathic (1) 
bleeding 
improved despite 
poor plt increment 
Quinidine (2) 
bleeding 
decreased or 
stopped 
(Chandram
ouli and 
Rodgers 
2000) 
NR 2 F (2) Autoimmune 
associated 
NR 
(20 to 71) 
Large 
retroperiton
eal bleed 
(1) 
2 IVIG continuous 
24-hr infusion + 
concomitant 
apheresis plt tx 
(1/2 pheresis 
pack every 4 
hrs) 
Plt count >100 × 109 NR 
(Spahr and 
Rodgers 
2008) 
Jan 
2000 - 
Dec 
2005 
40 M 
(23) 
F 
(17) 
Idiopathic 
(9 
previously 
refractory to 
IVIG alone) 
52  
(19 to 87) 
33 pts 38 (usually 
1 
mg/kg/day) 
IVIG (1 g/kg) 
continuous 
infusion over 24 
hrs 
51% achieved plt 
count >50 × 109/L by 
24 hrs 
Bleeding 
controlled initially 
in all pts 
regardless of plt 
count 
71 
 
Plt apheresis 
unit (1 unit 
every 8 hrs) 
 52 
CNS = central nervous system; F = female; GI = gastrointestinal; IVIG = intravenous immune globulin; ITP = autoimmune thrombocytopenia; M = male; NR = 53 
not reported; plt = platelet; pt = patient; pts = patients; Rx = treatment; tx = transfusion. 54 
 55 
56 
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Table VIII: Studies that reported the use of platelet transfusions in patients with thrombotic thrombocytopenic purpura 57 
and mortality in those receiving or not receiving platelet transfusion 58 
 59 
Study 
Type of 
Study 
Study 
Period 
No. of 
centres 
Country 
Number 
of 
Patients 
Number 
Received 
Plasma 
Therapy 
Number 
Received 
Platelet 
Tx 
Mortality§ 
Plt Tx 
Thrombosis 
Plt Tx 
Mortality§ 
Non-Plt 
Tx 
Thrombosis 
Non-Plt Tx 
Definition of 
TTP 
(Rutkow 1978) Unclear from the text that only one of the patients received platelet transfusions. One patient received plt Tx and survived. 
(Taft 1979) Unclear NR 
Single 
centre 
USA 4 4 TPE 3 1 NR 0 NR NR 
(Gottschall, et 
al 1981) 
Observational; 
Retrospective 
1974 
to 
1979 
Single 
centre 
USA 11 
11 WBE 
3 TPE 
8 (inc 4 
FWB) 
3 NR 0 NR  
CNS 
abnormalities 
MAHA 
(Byrnes 1981) 
Observational; 
retrospective 
NR 
Multicentre 
(NR) 
USA, S. 
America 
18 18 TPE 1 0 NR 5 NR MAHA 
(Liu, et al 
1986) 
Observational; 
Retrospective 
NR 
Single 
centre 
USA 8 8 TPE 7 0 NR 1 NR 
CNS 
abnormalities, 
MAHA, 
thrombocytopenia 
(Gordon, et al 
1987) 
    15  2 1  3   
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(Rose and 
Eldor 1987)* 
Observational; 
Retrospective 
1977 
to 
1985 
Multicentre 
(15) 
Israel & 
USA 
38 37 14 5 NR 1 NR 
Plt count < 100 x 
109/l, MAHA, 
neurology (major 
criteria) 
Fever, renal 
abnormalities 
supportive 
(McCarthy, et 
al 1994) 
Observational; 
Retrospective 
1973 
to 
1994 
Single 
centre 
USA 55 55 TPE 25 13 NR 2 NR NR 
(Goodnough, et 
al 1994) 
Observational; 
Retrospective 
NR§ 
Single 
centre 
USA 39 39 22 10 NR 3 NR 
Plt count < 150 x 
109/l, MAHA 
 60 
(Egerman, et 
al 1996) 
Observational; 
Retrospective 
Jan 
1988 
to Feb 
1996 
Single 
centre 
USA 11 
8 TPE 
3 HPI 
5 1 NR 1 NR 
Plt count < 100 x 
109/l, MAHA 
(Sarode, et al 
1997) 
Observational; 
Retrospective 
Jan 
1985 
to Jun 
1995 
Single 
centre 
USA 70 68 TPE 4 0 NR 
10 (2 died 
before 
TPE) 
NR 
Plt count < 100 x 
109/l, MAHA, 
neurological 
symptoms and/or 
renal impairment 
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(Coppo, et al 
2003) *† 
Observational; 
Retrospective 
1989 
to 
2001 
Single 
centre 
France 37 
19 HPI 
18 TPE 
8 1 NR 4 NR 
Plt count < 100 x 
109/l & MAHA 
with no known 
cause 
(Shamseddine, 
et al 2004)* 
Observational; 
Retrospective 
1980 
to 
2003 
Single 
centre 
Lebanon 47 
40 TPE 
 7 HPI 
4 2 NR 7 NR 
Plt count < 100  x 
109/l & MAHA 
with no known 
cause 
(Swisher, et al 
2009)* ǂ 
Observational; 
Retrospective 
Nov 
1995 
to Dec 
2007 
Single 
centre 
USA 54 49 TPE 33 
8 (2 died 
before 
TPE) 
5 died 
5 (3 died 
before 
TPE) 
4 died 
Plt count < 100  x 
109/l, MAHA 
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Table IX: Data from SHOT Annual Report 2013 (Bolton-Maggs, et al 2014) 63 
 64 
Adverse Event Estimated Risk per Unit of Platelets in the UK 
Febrile non-haemolytic transfusion reaction (excluding 
mild) 
1 in 6,000 
Allergic (excluding mild) 1 in 6,000 
Bacterial sepsis Rare since introduction of bacterial screening 2010 
Transfusion-related acute lung injury (TRALI) Less than 1 in 1,000,000 
Haemolysis from ABO incompatible plasma 1 in 600,000 
Hepatitis B infection 1 in 1,000,000 
Hepatitis C infection 1 in 30,000,000 
Human immunodeficiency (HIV) infection 1 in 7,000,000 
 65 
 66 
67 
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Table X: Platelet transfusion in times of shortage 68 
 69 
Category 1 Category 2 Category 3 
Massive haemorrhage & Critical care 
 Massive transfusion for any condition including obstetrics, 
emergency surgery and trauma, with on-going bleeding, 
maintain platelet count > 50 x 109/L. Aim for platelet count 
>100 x 109/L if multiple trauma or CNS trauma  
 
Bleeding in the presence of acute DIC, maintain >50x 
109/L. 
Critical care  
Patients resuscitated following 
massive transfusion with no on-going 
active bleeding, maintain platelet 
count > 50 x 109/L  
Surgery Urgent but not emergency 
surgery for a patient requiring platelet 
support 
Transfusion triggers for invasive 
procedures 
According to BCSH guideline 
 
Surgery 
Elective, non-urgent surgery 
likely to require platelet 
support for thrombocytopenia 
or congenital/ acquired 
platelet defects 
 
 
Bone marrow failure 
 Active bleeding associated with severe thrombocytopenia 
or functional platelet defects 
Immune thrombocytopenia if serious/life-threatening 
bleeding 
Bone marrow failure 
All other indications except those in 
category 1 or 3 
Bone marrow failure 
Prophylactic transfusion of 
stable patients following 
autologous stem cell 
transplant. 
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Neonates For neonatal alloimmune thrombocytopenia or 
severe thrombocytopenia in an otherwise well neonate, 
platelet transfusions are required when the platelet count 
falls to between 20 –30 x 109/L. Higher target levels should 
be maintained if extremely low birth weight or 
unwell/bleeding or Intra-cranial haemorrhage 
suspected/confirmed. 
  
DIC, disseminated intravascular coagulation; CNS = central nervous system70 
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Platelet transfusion: principles, risks, alternatives and best practice 71 
 72 
Platelet transfusions are an essential component in the management of selected patients with 73 
thrombocytopenia. However they need to be used judiciously as they are a limited resource and are not risk 74 
free. 75 
 76 
Classification of conditions which may require platelet transfusion 77 
 Bone marrow failure (BMF).  Reversible associated with treatable disease and/or chemotherapy and 78 
occasionally chronic (irreversible) BMF e.g. myelodysplastic syndromes 79 
 Thrombocytopenia in critical care 80 
 Peripheral platelet consumption/destruction e.g. disseminated intravascular coagulation and immune 81 
thrombocytopenia 82 
 Abnormal platelet function. Inherited or acquired disorders e.g. anti-platelet agents, uraemia 83 
  84 
Principles of platelet transfusion 85 
 86 
Platelets are used in 3 distinct situations –  87 
- Prophylactic (WHO bleeding grade 0 or 1) to prevent bleeding 88 
o Routine use in non-bleeding patients 89 
o In the presence of additional risk factors for bleeding e.g. sepsis or abnormalities of haemostasis 90 
- Pre-procedure to prevent bleeding expected to occur during surgery/invasive procedure 91 
- Therapeutic (WHO bleeding grade > 2)  to treat active bleeding 92 
Contraindications to platelet transfusion unless life-threatening haemorrhage 93 
 Thrombotic Thrombocytopenic Purpura (TTP) 94 
Risks associated with platelet transfusion 95 
 96 
Reduced effectiveness of future platelet transfusion   
Alloimmunisation 
Adverse effects 
Febrile non-haemolytic transfusion reactions (FNHTR) and allergic reactions (including mild), reported incidence up 
to 3%. May require investigation to exclude other causes and prolong hospital stay. 
Estimated risk of moderate/severe reactions and infection transmission 
FNHTR 1 in 6,000 
Allergic 1 in 6,000 
Haemolysis 1 in 600,000 
Bacterial sepsis Rare since bacterial screening 2010 
Transfusion Related Acute Lung Injury Less than 1 in 1,000,000 
Hepatitis B infection  1 in 1,000,000 
Appendix 1 
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Hepatitis C infection 1 in 30,000,000 
HIV infection 1 in 7,000,000 
Possible alternatives to platelet transfusion 97 
Apply surface pressure after superficial procedures and correct surgical causes for bleeding 
Surgical patients expected to have at least a 500 ml blood loss, use tranexamic acid (TXA) unless contraindicated 
Trauma patients who are bleeding/ at risk of bleeding, early use of TXA 
Severe bleeding replace fibrinogen if plasma concentration less than 1.5 g/L  
Anti-platelet agents  - discontinue or if urgent procedure/bleeding use TXA if risk/benefit would support 
Uraemia with bleeding or preprocedure – dialyse, correct anaemia, consider desmopressin 
Inherited platelet function disorders - specialist haematology advice required. Consider desmopressin 
Chronic BMF with bleeding – consider TXA 
Prior to prescribing a platelet transfusion consider – 98 
 What are the indications for transfusion in this patient? 99 
 Are there alternatives which could be used in preference to platelet transfusion? 100 
 Has the indication been documented in the patients’ record and on the transfusion request form? 101 
 Has the patient consented to receive a platelet transfusion?102 
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Indications for use of platelet transfusion in adults 103 
Indication Transfusion indicated 
(threshold)/not indicated 
Prophylactic use (No bleeding or WHO grade 1)  
One adult dose required 
- Reversible bone marrow failure (BMF) including allogeneic stem cell transplant 
- Reversible BMF with autologous stem cell transplant (consider no prophylaxis) 
- Critical illness 
- Chronic BMF receiving intensive therapy 
- Chronic BMF to prevent persistent bleeding of grade > 2 
 
 
10 x 109/L 
10 x 109/L 
10 x 109/L 
10 x 109/L 
Count variable  
- Chronic stable BMF, abnormal platelet function, platelet consumption/ destruction 
(e.g. DIC, TTP) or immune thrombocytopenia (ITP, HIT, PTP)   
 
Not indicated 
Prophylactic use in the presence of risk factors for bleeding (e.g. sepsis, 
antibiotic treatment, abnormalities of haemostasis) 
- Reversible/chronic bone marrow failure/critical care 
 
 
10 to 20 x 109/L 
- Abnormal platelet function, platelet consumption/destruction, immune 
thrombocytopenia  
 
 
Not indicated 
Platelet transfusion preprocedure 
- Central venous catheter (CVC) excluding PICC line 
- Lumbar puncture 
- Percutaneous liver biopsy 
- Major surgery 
- Epidural anaesthesia, insertion & removal 
- Neurosurgery or ophthalmic surgery involving the posterior segment of the eye  
 
20 x 109/l 
40 x 109/l 
50 x 109/l 
50 x 109/l 
80 x 109/l 
100 x 109/l 
Bone marrow aspirate or trephine biopsies, PICC line insertion, traction removal of 
central venous catheters (CVCs), cataract surgery 
 
Not  indicated 
 Specific clinical conditions – see below for indications   
Therapeutic use (Bleeding WHO grade 2 or above) 
- Severe bleeding  
- Multiple trauma, brain or eye injury, spontaneous intracerebral haemorrhage   
- Bleeding (WHO grade >2) but not severe 
 
50 x 109/L 
100 x 109/L 
30 x 109/L 
- Bleeding in specific clinical conditions – see below for indications  
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Specific clinical conditions 
Platelet function defect 
- Congenital – Preprocedure or therapeutic use. When alternative therapy 
   contraindicated or ineffective. Directed by specialist in haemostasis. 
- Acquired (anti-platelet agents, uraemia)- only indicated for severe bleeding 
Disseminated intravascular bleeding Preprocedure or therapeutic use. Consider 
threshold counts above but may not be achievable and individual case review 
required. 
Thrombotic thrombocytopenic purpura Platelet transfusion contraindicated unless 
life-threatening bleeding 
Immune thrombocytopenia (ITP, HIT, PTP). Pre-procedure when other therapy 
ineffective/procedure urgent or to treat severe bleeding. Consider threshold counts 
above but may be unachievable or unnecessary and individual case review 
required. 
 
 
Count variable 
 
 
 
Use preprocedure / 
therapeutic  threshold as 
guide 
Count variable 
 
Use preprocedure / 
therapeutic threshold as 
guide 
 104 
Disseminated intravascular coagulation (DIC),  peripherally inserted central catheter (PICC), 105 
thrombotic thrombocytopenic purpura (TTP), primary immune thrombocytopenia (ITP), heparin-106 
induced thrombocytopenia (HIT), post-transfusion purpura (PTP) 107 
 108 
 109 
